| Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 7159763 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate than an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity. |
| | |
Authors:
|
P J Burke; J E Karp; W P Vaughan; P L Sanford |
Related Documents
:
|
17854773 - Orotate phosphoribosyltransferase expression level in tumors is a potential determinant... 22253413 - Here, there be dragons: charting autophagy-related alterations in human tumors. 16140583 - Chimeric dna vaccine reverses morphine-induced immunosuppression and tumorigenesis. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Blood cells Volume: 8 ISSN: 0340-4684 ISO Abbreviation: Blood Cells Publication Date: 1982 |
Date Detail:
|
Created Date: 1983-04-15 Completed Date: 1983-04-15 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7513567 Medline TA: Blood Cells Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: 519-33 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Animals Cell Division / drug effects Cell Survival / drug effects Cells, Cultured Cytarabine / therapeutic use* Dose-Response Relationship, Drug Drug Administration Schedule Humans Leukemia / drug therapy*, pathology Leukemia, Experimental / drug therapy Rats |
| Grant Support | |
ID/Acronym/Agency:
|
CA-066973/CA/NCI NIH HHS; CA-23973/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
147-94-4/Cytarabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of leukemic cell chromosomes as a guide to therapy.
Next Document: White cell differential: coupling of cell types in patients undergoing chemotherapy.